应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
LLY 礼来
已收盘 07-26 16:00:00 EDT
804.62
-16.57
-2.02%
盘后
804.60
-0.02
+0.00%
19:59 EDT
最高
822.01
最低
801.30
成交量
417.39万
今开
811.87
昨收
821.19
日振幅
2.52%
总市值
7,647亿
流通市值
7,628亿
总股本
9.50亿
成交额
33.81亿
换手率
0.44%
流通股本
9.48亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
“劲敌”接踵而至 礼来市值蒸发逾1200亿美元 “诺礼双雄”终被打破？
智通财经 · 07-26 13:13
“劲敌”接踵而至 礼来市值蒸发逾1200亿美元 “诺礼双雄”终被打破？
礼来(LLY)盘前一度跌1.12% 投资者认为礼来在减肥药市场主导地位可能终结
金吾财讯 · 07-26 20:49
礼来(LLY)盘前一度跌1.12% 投资者认为礼来在减肥药市场主导地位可能终结
礼来拐点？两日蒸发1000亿美金！辉瑞基因疗法获欧盟批准，罗氏诊断上半年营收近600亿
医药经济报 · 07-26 18:16
礼来拐点？两日蒸发1000亿美金！辉瑞基因疗法获欧盟批准，罗氏诊断上半年营收近600亿
不止“减肥药双雄”，基金经理点名存在估值机会的股票，并称市场大到可以容纳三到四家公司
老虎资讯综合 · 07-26 11:45
不止“减肥药双雄”，基金经理点名存在估值机会的股票，并称市场大到可以容纳三到四家公司
Viking Therapeutics暴涨近30%，最新研究可能撼动减肥药市场，吓坏两大市场巨头
老虎资讯综合 · 07-26 07:36
Viking Therapeutics暴涨近30%，最新研究可能撼动减肥药市场，吓坏两大市场巨头
礼来下跌5.11%，报815.97美元/股
金融界 · 07-25 22:12
礼来下跌5.11%，报815.97美元/股
礼来盘中异动 快速跳水5.08%
自选股智能写手 · 07-25 22:03
礼来盘中异动 快速跳水5.08%
全球第一家万亿美元市值的医药公司呼之欲出
证券市场周刊 · 07-25 17:31
全球第一家万亿美元市值的医药公司呼之欲出
降息在即！这些股票将受益并迎来上涨机会
金十数据 · 07-24 15:06
降息在即！这些股票将受益并迎来上涨机会
Biotech如何优雅地把自己卖出高价？
投资界 · 07-24
Biotech如何优雅地把自己卖出高价？
礼来上涨1.34%，报877.6美元/股
金融界 · 07-23
礼来上涨1.34%，报877.6美元/股
礼来(LLY)盘前涨1.4% 在华肥胖治疗领域首个创新药物替尔泊肽注射液获批
金吾财讯 · 07-22
礼来(LLY)盘前涨1.4% 在华肥胖治疗领域首个创新药物替尔泊肽注射液获批
美股减肥药板块走势分化 诺和诺德(NVO.US)、礼来(LLY.US)双头垄断格局面临挑战
智通财经 · 07-22
美股减肥药板块走势分化 诺和诺德(NVO.US)、礼来(LLY.US)双头垄断格局面临挑战
重磅！礼来“减肥针”国内最新获批，司美的最强对手来了？
华尔街见闻 · 07-21
重磅！礼来“减肥针”国内最新获批，司美的最强对手来了？
减肥药赛道“搅局者”来了，两大巨头“硬碰硬”
中国基金报 · 07-20
减肥药赛道“搅局者”来了，两大巨头“硬碰硬”
减肥药赛道“搅局者”来了，两大巨头“硬碰硬”
中国基金报 · 07-20
减肥药赛道“搅局者”来了，两大巨头“硬碰硬”
司美格鲁肽的竞争对手来了 礼来替尔泊肽注射液体重管理适应症获批
每日经济新闻 · 07-19
司美格鲁肽的竞争对手来了 礼来替尔泊肽注射液体重管理适应症获批
礼来(LLY)盘前涨超2% 减重适应症获国家药品监督管理局批准
金吾财讯 · 07-19
礼来(LLY)盘前涨超2% 减重适应症获国家药品监督管理局批准
礼来减肥药在中国获批，将和诺和诺德直接竞争
智通财经 · 07-19
礼来减肥药在中国获批，将和诺和诺德直接竞争
BUZZ-减肥药在中国获批，礼来公司业绩上升
Reuters · 07-19
BUZZ-减肥药在中国获批，礼来公司业绩上升
加载更多
公司概况
公司名称：
礼来
所属市场：
NYSE
上市日期：
--
主营业务：
礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。
发行价格：
--
{"stockData":{"symbol":"LLY","market":"US","secType":"STK","nameCN":"礼来","latestPrice":804.62,"timestamp":1722024000000,"preClose":821.19,"halted":0,"volume":4173942,"hourTrading":{"tag":"盘后","latestPrice":804.6,"preClose":804.62,"latestTime":"19:59 EDT","volume":328744,"amount":264504110.108401,"timestamp":1722038398994},"delay":0,"floatShares":948000000,"shares":950405386,"eps":6.79045,"marketStatus":"已收盘","marketStatusCode":5,"change":-16.57,"latestTime":"07-26 16:00:00 EDT","open":811.87,"high":822.01,"low":801.3,"amount":3380736079.7808,"amplitude":0.025219,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.79045,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1722240000000},"adr":0,"listingDate":102488400000,"adjPreClose":821.19,"adrRate":0,"dividendRate":0.005829,"preHourTrading":{"tag":"盘前","latestPrice":810.82,"preClose":821.19,"latestTime":"09:29 EDT","volume":16573,"amount":13526451.702,"timestamp":1722000597431},"postHourTrading":{"tag":"盘后","latestPrice":804.6,"preClose":804.62,"latestTime":"19:59 EDT","volume":328744,"amount":264504110.108401,"timestamp":1722038398994},"volumeRatio":1.229903,"impliedVol":0.412,"impliedVolPercentile":0.9603},"requestUrl":"/m/hq/s/LLY/","defaultTab":"news","newsList":[{"id":"2454350754","title":"“劲敌”接踵而至 礼来市值蒸发逾1200亿美元 “诺礼双雄”终被打破？","url":"https://stock-news.laohu8.com/highlight/detail?id=2454350754","media":"智通财经","labels":[],"top":1,"share":"https://www.laohu8.com/m/news/2454350754?lang=zh_cn&edition=full","pubTime":"2024-07-26 13:13","pubTimestamp":1721970788,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，由于至少有两家竞争对手在治疗减肥方面取得了令人鼓舞的进展，礼来作为减肥药热潮领军企业的地位正受到威胁，过去八天市值蒸发逾1200亿美元。在过去的八个交易日里，礼来股价累计下跌14%，这是该股自2020年以来表现最糟糕的八个交易日。礼来的市值现已跌破了8000亿美元，不过今年迄今仍上涨了约41%。","market":"hk","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1155956.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"“劲敌”接踵而至 礼来市值蒸发逾1200亿美元 “诺礼双雄”终被打破？","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1267930730.SGD","BK4585","LU0289739699.SGD","NVO","IE00B2B36J28.USD","LU0198837287.USD","IE0002141913.USD","LU0456855351.SGD","BK4581","IE00BJJMRZ35.SGD","LU0820561909.HKD","LU1623119135.USD","BK4007","LU0466842654.USD","LU0320765059.SGD","LU1064131342.USD","LU0096364046.USD","LU1551013425.SGD","VKTX","IE00BJLML261.HKD","GB00BDT5M118.USD","LU0640476718.USD","LU0882574055.USD","LU1061106388.HKD","LU0256863902.USD","LU0943347566.SGD","LU1712237335.SGD","LU0823416689.USD","LU1804176565.USD","LU0097036916.USD","IE0004445239.USD","LU0820561818.USD","LU0114720955.EUR","LU0385154629.USD","IE00BK4W5L77.USD","LU0417517546.SGD","BK4588","LU1069344957.HKD","IE00BK4W5M84.HKD","LU0471298777.SGD","LU0882574139.USD","LLY","LU0079474960.USD","IE00BFTCPJ56.SGD","LU0689472784.USD","IE0009355771.USD","BK4516","LU0238689110.USD","LU0256863811.USD","LU0672654240.SGD","LU1551013342.USD","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2454344769","title":"礼来(LLY)盘前一度跌1.12% 投资者认为礼来在减肥药市场主导地位可能终结","url":"https://stock-news.laohu8.com/highlight/detail?id=2454344769","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454344769?lang=zh_cn&edition=full","pubTime":"2024-07-26 20:49","pubTimestamp":1721998170,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来 盘前续跌，一度跌1.12%，报812美元。隔夜收跌4.5%，跌至5月以来的最低水平。过去八个交易日，该公司股价下跌了 14%，这是自 2020 年以来最糟糕的八天。过去一周， Viking Therapeutics 和 Roche Holding AG 发布减肥药新消息，引发了礼来股价的下跌。此次股价暴跌表明，随着竞争对手逐渐接近可行的竞争药物，投资者认为礼来和 Novo Nordisk A/S 在减肥药市场的主导地位可能终结——到 2030 年，该市场规模有望达到 1300 亿美元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/MzE4MDg0MTAxNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MzE4MDg0MTAxNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278256","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574139.USD","LU0198837287.USD","LU0114720955.EUR","LU0385154629.USD","LU0943347566.SGD","LU1551013425.SGD","LU0466842654.USD","LU0823416689.USD","LU1023059063.AUD","LU1064131342.USD","GB00BDT5M118.USD","IE0009355771.USD","BK4588","LLY","LU0471298777.SGD","IE00BK4W5M84.HKD","LU0238689110.USD","LU0061475181.USD","LU0096364046.USD","LU1551013342.USD","LU1804176565.USD","LU0640476718.USD","LU0289739699.SGD","LU0079474960.USD","IE00BK4W5L77.USD","LU1061106388.HKD","IE00B4R5TH58.HKD","LU0882574055.USD","BK4534","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU0097036916.USD","LU1267930730.SGD","IE0002141913.USD","LU0256863902.USD","LU1623119135.USD","LU0820561909.HKD","BK4516","BK4581","LU0672654240.SGD","LU1069344957.HKD","BK4585","LU0094547139.USD","LU1712237335.SGD","LU1057294990.SGD","LU0820561818.USD","LU0320765059.SGD","LU0689472784.USD","LU0417517546.SGD","IE00B2B36J28.USD"],"gpt_icon":1},{"id":"2454314840","title":"礼来拐点？两日蒸发1000亿美金！辉瑞基因疗法获欧盟批准，罗氏诊断上半年营收近600亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2454314840","media":"医药经济报","labels":["Product Release","Business Data"],"top":-1,"share":"https://www.laohu8.com/m/news/2454314840?lang=zh_cn&edition=full","pubTime":"2024-07-26 18:16","pubTimestamp":1721988987,"startTime":"0","endTime":"0","summary":"辉瑞于2014年12月以2000万美元预付款从Spark Therapeutics获得该疗法。截止目前，KN057已经获得两项由FDA授予的孤儿药资格。目前，KN057正在中国开展两项3期临床研究。礼来两日蒸发1000亿美金7月25日以来，全球市值最高的药企礼来制药的市值蒸发了1000亿美元。如不及时治疗，会造成受累脏器的不可逆损害，最终导致患者死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726183128955d2a9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726183128955d2a9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LLY","PFE"],"gpt_icon":1},{"id":"1136187782","title":"不止“减肥药双雄”，基金经理点名存在估值机会的股票，并称市场大到可以容纳三到四家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1136187782","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1136187782?lang=zh_cn&edition=full","pubTime":"2024-07-26 11:45","pubTimestamp":1721965537,"startTime":"0","endTime":"0","summary":"减肥药在过去一年左右引起了投资者的兴趣，并撼动了其他行业。Tema ETFs的基金经理Yuri Khodjamirian表示，这两家公司构成了一个“非常强大的双头垄断”。“我认为市场大到可以容纳三到四家公司，即使是现在已经存在的市值，但市场正在试图找出第三或第四个玩家，而一个重大的突破可能是口服GLP-1药物，”他说。GLP-1是一种在肠道中释放的激素，能刺激胰岛素分泌，延缓胃排空并向大脑传递饱腹感。他说，目前生物技术股票存在“估值机会”，但也警告了风险。","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","VKTX","AMGN","LLY"],"gpt_icon":1},{"id":"1155648411","title":"Viking Therapeutics暴涨近30%，最新研究可能撼动减肥药市场，吓坏两大市场巨头","url":"https://stock-news.laohu8.com/highlight/detail?id=1155648411","media":"老虎资讯综合","labels":["analysis"],"top":-1,"share":"https://www.laohu8.com/m/news/1155648411?lang=zh_cn&edition=full","pubTime":"2024-07-26 07:36","pubTimestamp":1721950589,"startTime":"0","endTime":"0","summary":"$Viking Therapeutics$ 的股票在周四飙升28.31%，因为该公司宣布正在研究其减肥药的每月剂量。此前，Viking计划进行二期B阶段的研究。两家公司分别通过Zepbound和Wegovy主导减肥药市场，但它们的每周注射药物面临短缺，这意味着竞争对手有机会进入市场。而Viking是首个宣布潜在每月注射方案的公司。Viking Therapeutics股票表现强劲 Viking Therapeutics的消息对礼来的股票特别不利。他对Viking Therapeutics的股票给予了“优于大盘”的评级。口服减肥药市场也在升温。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Viking Therapeutics减肥药物研究取得重大进展,股价大涨28%","news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","NVO","VKTX"],"gpt_icon":1},{"id":"2454587291","title":"礼来下跌5.11%，报815.97美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2454587291","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454587291?lang=zh_cn&edition=full","pubTime":"2024-07-25 22:12","pubTimestamp":1721916721,"startTime":"0","endTime":"0","summary":"7月25日，礼来(LLY)盘中下跌5.11%，截至22:12，报815.97美元/股，成交8.55亿美元。财务数据显示，截至2024年03月31日，礼来收入总额87.68亿美元，同比增长25.98%；归母净利润22.43亿美元，同比增长66.77%。大事提醒：8月8日，礼来将于(美东)盘前披露2024财年中报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/25221241811851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU1280957306.USD","IE00BFTCPJ56.SGD","LU0471298694.HKD","LU1712237335.SGD","BK4007","LU0256863902.USD","LU0466842654.USD","LU1623119135.USD","LLY","LU0079474960.USD","LU1061106388.HKD","LU0058720904.USD","BK4585","IE0004445239.USD","BK4533","IE00B2B36J28.USD","LU0256863811.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU0689472784.USD","LU0320765059.SGD","LU0097036916.USD","LU0820561818.USD","LU0820561909.HKD","LU1064131342.USD","LU1267930730.SGD","LU1551013425.SGD","LU0385154629.USD","LU0943347566.SGD","LU0471298777.SGD","LU0823416689.USD","LU0114720955.EUR","LU0456855351.SGD","BK4534","LU0882574055.USD","LU0238689110.USD","LU0640476718.USD","LU0882574139.USD","LU1804176565.USD","BK4516","LU1551013342.USD","IE00B4R5TH58.HKD","LU1069344957.HKD","IE0002141913.USD","GB00BDT5M118.USD","LU0198837287.USD","LU0122379950.USD","BK4588","IE00BJLML261.HKD"],"gpt_icon":1},{"id":"2454874518","title":"礼来盘中异动 快速跳水5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454874518","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454874518?lang=zh_cn&edition=full","pubTime":"2024-07-25 22:03","pubTimestamp":1721916236,"startTime":"0","endTime":"0","summary":"北京时间2024年07月25日22时03分，礼来股票出现波动，股价快速下跌5.08%。礼来股票所在的制药行业中，整体跌幅为1.68%。礼来制药公司的主要产品包括治疗癌症的 Verzenio；用于治疗糖尿病的 Mounjaro、Zepbound、Jardiance、Trulicity、Humalog 和 Humulin；以及免疫学方面的 Taltz 和 Olumiant。罗氏在上周三宣布，其第二款候选减肥药CT-996显著减轻了患者的体重。诺和诺德将于美东时间8月8日公布第二季度业绩。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725220359af941f5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725220359af941f5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LLY","LU0109391861.USD","IE00BK4W5L77.USD","LU0238689110.USD","LU1551013425.SGD","LU0417517546.SGD","LU0672654240.SGD","IE0002141913.USD","LU1023059063.AUD","LU0471298694.HKD","LU0471298777.SGD","LU0122379950.USD","BK4534","LU0198837287.USD","LU1057294990.SGD","IE00B2B36J28.USD","LU0943347566.SGD","LU0079474960.USD","LU0456855351.SGD","LU1280957306.USD","LU0256863902.USD","LU0256863811.USD","LU0320765059.SGD","LU1064131342.USD","LU1267930730.SGD","IE00BJJMRZ35.SGD","LU0061475181.USD","IE00B1BXHZ80.USD","LU1035775433.USD","BK4007","LU0640476718.USD","LU0823416689.USD","LU1061106388.HKD","BK4581","IE00B4R5TH58.HKD","LU0882574055.USD","LU0708995401.HKD","LU0289739699.SGD","IE00BK4W5M84.HKD","IE0004445239.USD","IE00BJLML261.HKD","BK4585","LU0058720904.USD","LU1804176565.USD","GB00BDT5M118.USD","LU0094547139.USD","LU1551013342.USD","BK4588","BK4533","IE00BJT1NW94.SGD"],"gpt_icon":1},{"id":"2454842006","title":"全球第一家万亿美元市值的医药公司呼之欲出","url":"https://stock-news.laohu8.com/highlight/detail?id=2454842006","media":"证券市场周刊","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454842006?lang=zh_cn&edition=full","pubTime":"2024-07-25 17:31","pubTimestamp":1721899865,"startTime":"0","endTime":"0","summary":"文丨刘翎在英伟达、苹果、微软等公司争夺全球最大市值上市公司的过程中，医药板块有家公司，凭借自身卓越的研发能力和长远布局，可能会成为全球第一家市值超过万亿美元的医药上市公司。礼来公司成立于1876年，在其悠久且卓越的公司历史上，其是世界上第一家大规模生产胰岛素的公司。目前，礼来公司产品覆盖精神疾病、心血管、肿瘤、自免等领域，是一家全球知名的平台型医药公司。全球预计超过2000亿美元。全球患者预计将近5000万人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407251735469ee97405&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407251735469ee97405&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJJMRZ35.SGD","LU1064131342.USD","LU0238689110.USD","LU0114720955.EUR","LU0689472784.USD","LU0154236417.USD","LU0256863902.USD","LU0640476718.USD","BK4588","LU0820561818.USD","LU0256863811.USD","LU1093756325.SGD","NVO","LU1551013342.USD","LU1623119135.USD","IE00BKVL7J92.USD","LU1267930730.SGD","IE00B2B36J28.USD","LU0417517546.SGD","BK4581","IE0009355771.USD","LU0096364046.USD","LU0198837287.USD","IE00B4R5TH58.HKD","LU0456855351.SGD","GB00BDT5M118.USD","IE00BJLML261.HKD","LU0820561909.HKD","LU0672654240.SGD","IE00BZ1G4Q59.USD","BK4585","IE0002141913.USD","LU0320765059.SGD","LU0943347566.SGD","LU0882574055.USD","LU0079474960.USD","LU0385154629.USD","LU0466842654.USD","LU0882574139.USD","LU0471298777.SGD","LU1061106388.HKD","LU1069344957.HKD","LU1712237335.SGD","LU0823416689.USD","LLY","IE00BFTCPJ56.SGD","LU0097036916.USD","BK4516","LU1804176565.USD","LU1551013425.SGD"],"gpt_icon":1},{"id":"2453616029","title":"降息在即！这些股票将受益并迎来上涨机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2453616029","media":"金十数据","labels":["Economic Data"],"top":-1,"share":"https://www.laohu8.com/m/news/2453616029?lang=zh_cn&edition=full","pubTime":"2024-07-24 15:06","pubTimestamp":1721804800,"startTime":"0","endTime":"0","summary":"市场预测美联储将在9月启动降息，为经济带来宽松的货币政策。随着降息预期的升温，股票市场已经提前反应，接近历史高点。","market":"hk","thumbnail":"https://img.jin10.com/gallary/c40c0b04-c780-4fae-8a17-73b8cb5cb986.png/lite","type":0,"news_type":0,"thumbnails":["https://img.jin10.com/gallary/c40c0b04-c780-4fae-8a17-73b8cb5cb986.png/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=144126&type=news&data_type=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Economic Data","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["LU1548497426.USD","LLY","LU1974910355.USD","LU0198837287.USD","SDS","SPXU","IE00B19Z9Z06.USD","LU2355687059.USD","IE00BZ9MQY76.HKD","DDOG","CRM","OEF","LU0719512351.SGD","BK4529","IE0005OL40V9.USD","MRK","LU0742534661.SGD","BK4212","IVV","LU0889565916.HKD","ESmain","LU0456855351.SGD","BK4560","NET","SSO","BK4528","LU0965509010.AUD","SH","IE00B4R5TH58.HKD","LW","UPRO","RSG","LU0320765489.SGD",".SPX","IE00B4JS1V06.HKD","LU0256863902.USD","LU2433249047.HKD","REGN","SPY","BK4561","ZS","LU0234570918.USD","LU0820562030.AUD","LU0985320562.USD","LU0266013472.USD","BK4527","OEX"],"gpt_icon":1},{"id":"2453016349","title":"Biotech如何优雅地把自己卖出高价？","url":"https://stock-news.laohu8.com/highlight/detail?id=2453016349","media":"投资界","labels":["Company Corporation"],"top":-1,"share":"https://www.laohu8.com/m/news/2453016349?lang=zh_cn&edition=full","pubTime":"2024-07-24 08:48","pubTimestamp":1721782088,"startTime":"0","endTime":"0","summary":"在寒意尚未褪去的当下，如何将一家亏损了10年的biotech卖个好价格？恐怕所有的biotech都想学习。Fortune Business Insights的一份报告指出，2023年全球炎症性肠病治疗市场规模为265.5亿美元，预计到2032年将会增长至440.8亿美元。去年9月7日，双方高管会面，讨论了Morphic的临床项目。自2022年低点以来，Morphic股价涨幅接近3倍，价格越来越贵。换句话说，尽管Morphic单吊礼来，也成功卖了一个高价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072409071095548154&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072409071095548154&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0882574055.USD","LU0820561818.USD","BK4585","LU0256863811.USD","LU0256863902.USD","IE00BJLML261.HKD","IE00B2B36J28.USD","LU0094547139.USD","LU0097036916.USD","IE0004445239.USD","LU0640476718.USD","LU0456855351.SGD","IE00B4R5TH58.HKD","LU1035775433.USD","LU0320765059.SGD","LU0820561909.HKD","LU0471298694.HKD","MRNA","BK4516","GB00BDT5M118.USD","LU1069344957.HKD","LU1267930730.SGD","BK4581","LU0943347566.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0882574139.USD","IE0009355771.USD","LU0198837287.USD","LU0079474960.USD","LLY","LU1623119135.USD","LU0471298777.SGD","IE00BK4W5L77.USD","RHI","LU1551013425.SGD","IE00BK4W5M84.HKD","BK4130","LU0466842654.USD","LU1551013342.USD","LU1712237335.SGD","LU0823416689.USD","LU0096364046.USD","LU1064131342.USD","LU1804176565.USD","LU0385154629.USD","LU0689472784.USD","BK4588","IE00BJJMRZ35.SGD","LU0114720955.EUR"],"gpt_icon":1},{"id":"2453058379","title":"礼来上涨1.34%，报877.6美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453058379","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453058379?lang=zh_cn&edition=full","pubTime":"2024-07-23 22:00","pubTimestamp":1721743241,"startTime":"0","endTime":"0","summary":"7月23日，礼来(LLY)盘中上涨1.34%，截至22:00，报877.6美元/股，成交2.65亿美元。财务数据显示，截至2024年03月31日，礼来收入总额87.68亿美元，同比增长25.98%；归母净利润22.43亿美元，同比增长66.77%。大事提醒：8月8日，礼来将于(美东)盘前披露2024财年中报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/23220041748884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU1551013425.SGD","LU1023059063.AUD","BK4534","LU1069344957.HKD","LU1804176565.USD","LU0289739699.SGD","LU0820561909.HKD","LU1551013342.USD","IE00BJJMRZ35.SGD","LU0820561818.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU0079474960.USD","LU0823416689.USD","LU0882574055.USD","LU1623119135.USD","IE00B4R5TH58.HKD","GB00BDT5M118.USD","LU0882574139.USD","LU1064131342.USD","LU1712237335.SGD","BK4585","IE00BJLML261.HKD","IE0002141913.USD","LU0385154629.USD","IE00BK4W5L77.USD","BK4588","LU0471298777.SGD","LU0689472784.USD","LU0943347566.SGD","LLY","LU1267930730.SGD","LU0097036916.USD","LU0198837287.USD","LU0417517546.SGD","IE0009355771.USD","LU0320765059.SGD","LU0114720955.EUR","BK4516","LU0640476718.USD","LU0096364046.USD","LU0256863902.USD","LU0672654240.SGD","LU0456855351.SGD","BK4581","IE00B2B36J28.USD","IE00BK4W5M84.HKD","LU0466842654.USD","LU0256863811.USD","LU0238689110.USD"],"gpt_icon":1},{"id":"2453767981","title":"礼来(LLY)盘前涨1.4% 在华肥胖治疗领域首个创新药物替尔泊肽注射液获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2453767981","media":"金吾财讯","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453767981?lang=zh_cn&edition=full","pubTime":"2024-07-22 20:54","pubTimestamp":1721652874,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来(LLY)盘前走高，暂涨1.4%，报869.49美元。近期，国家药监局官网公示，礼来申报的穆峰达（替尔泊肽注射液）长期体重管理适应证获得批准，这也是礼来肥胖治疗领域在中国获批的首个创新药物。替尔泊肽注射液本次获批的适应症为：用于在低热量饮食和增加运动基础上改善成人肥胖或伴有至少一种体重相关合并症的超重患者长期体重管理。而在今年5月，替尔泊肽已经在中国获批首个适应症，用于成人2型糖尿病患者血糖控制。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/OGIwZDQyMDYwMGIwOWQ1NTkxMDE1Mzc1NTA2MDQ=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OGIwZDQyMDYwMGIwOWQ1NTkxMDE1Mzc1NTA2MDQ=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278057","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BK4W5M84.HKD","LU1035775433.USD","LU0079474960.USD","LLY","BK1161","LU1551013342.USD","LU0289739699.SGD","BK1574","BK4534","BK4588","IE00BJT1NW94.SGD","LU0238689110.USD","159992","IE0004445239.USD","LU1267930730.SGD","BK4516","LU0471298777.SGD","LU0417517546.SGD","IE00B1BXHZ80.USD","LU0471298694.HKD","LU1804176565.USD","LU1280957306.USD","LU1061106388.HKD","LU0096364046.USD","LU0094547139.USD","BK4533","GB00BDT5M118.USD","IE00BJLML261.HKD","LU1551013425.SGD","LU0672654240.SGD","LU0109391861.USD","06978","LU0882574055.USD","LU1023059063.AUD","LU0320765059.SGD","LU0256863902.USD","IE00BJJMRZ35.SGD","LU0122379950.USD","BK4007","IE00B4R5TH58.HKD","IE00BK4W5L77.USD","LU0943347566.SGD","LU1057294990.SGD","BK4581","LU0114720955.EUR","LU0058720904.USD","LU0256863811.USD","IE0002141913.USD","LU0708995401.HKD","LU0061475181.USD"],"gpt_icon":1},{"id":"2453768407","title":"美股减肥药板块走势分化 诺和诺德(NVO.US)、礼来(LLY.US)双头垄断格局面临挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2453768407","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453768407?lang=zh_cn&edition=full","pubTime":"2024-07-22 18:50","pubTimestamp":1721645400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月以来，美股减肥药板块走势分化。市场领导者诺和诺德、礼来股价均走低，而实力较强的追赶者罗氏、辉瑞、安进在7月分别累计上涨13%、7%和6%。诺和诺德将于美东时间8月8日公布第二季度业绩。市场对减肥药的火爆需求推动诺和诺德第一季度净利润同比增长28%，该公司还上调了全年营收与经营利润增速指引。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0061475181.USD","BK4533","LU0882574139.USD","IE0002141913.USD","LU0471298694.HKD","LU0882574055.USD","BK4585","IE00BJLML261.HKD","IE0009355771.USD","IE00BKVL7J92.USD","BK4534","LU1551013425.SGD","LU0820561818.USD","PFE","IE00B1BXHZ80.USD","LU0096364046.USD","GB00BDT5M118.USD","LU1712237335.SGD","LU0708995401.HKD","LU1093756325.SGD","LLY","LU1280957306.USD","LU0823416689.USD","LU1551013342.USD","BK4516","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","NVO","LU0820561909.HKD","IE0004445239.USD","LU0385154629.USD","LU1069344957.HKD","LU1061106388.HKD","LU0079474960.USD","BK4007","LU0122379950.USD","LU1804176565.USD","LU0466842654.USD","LU1093756168.USD","BK4532","LU0114720955.EUR","LU0943347566.SGD","LU0094547139.USD","LU0097036916.USD","LU0109391861.USD","LU0058720904.USD","LU0256863811.USD","LU0689472784.USD","LU1035775433.USD","LU1623119135.USD"],"gpt_icon":1},{"id":"2453217705","title":"重磅！礼来“减肥针”国内最新获批，司美的最强对手来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2453217705","media":"华尔街见闻","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453217705?lang=zh_cn&edition=full","pubTime":"2024-07-21 09:30","pubTimestamp":1721525428,"startTime":"0","endTime":"0","summary":"宿敌在前，新秀环伺，此次替尔泊肽减重适应证获批只是开始：中国的百亿“减肥针”市场，“双巨头”聚首、国产药逐鹿。","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/167c5259-53fc-47e3-806e-b6ff38af954e.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/167c5259-53fc-47e3-806e-b6ff38af954e.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3720297","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3720297","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["LU0061475181.USD","LU0820561818.USD","BK4585","LU0256863902.USD","IE00B2B36J28.USD","LU0094547139.USD","LU1057294990.SGD","LU0097036916.USD","LU0640476718.USD","LU0456855351.SGD","IE00B4R5TH58.HKD","LU1035775433.USD","LU0320765059.SGD","LU0820561909.HKD","LU1023059063.AUD","BK4516","LU1069344957.HKD","LU1267930730.SGD","BK4581","LU0943347566.SGD","IE00BFTCPJ56.SGD","LU0122379950.USD","LU0417517546.SGD","IE0009355771.USD","LU0198837287.USD","LU0882574139.USD","LLY","BK4534","NVO","LU1623119135.USD","LU0471298777.SGD","LU0708995401.HKD","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","IE00BJT1NW94.SGD","LU0466842654.USD","LU1712237335.SGD","IE00B1BXHZ80.USD","LU0823416689.USD","LU0058720904.USD","LU1280957306.USD","LU0672654240.SGD","LU0289739699.SGD","LU0096364046.USD","LU1064131342.USD","LU0109391861.USD","LU0238689110.USD","LU0385154629.USD","LU0689472784.USD","BK4588","LU0114720955.EUR"],"gpt_icon":1},{"id":"2452062894","title":"减肥药赛道“搅局者”来了，两大巨头“硬碰硬”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452062894","media":"中国基金报","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452062894?lang=zh_cn&edition=full","pubTime":"2024-07-20 00:16","pubTimestamp":1721405811,"startTime":"0","endTime":"0","summary":"国内减重赛道迎来重磅级“选手”。7月19日，记者从国家药品监督管理局获悉，礼来的替尔泊肽注射液长期体重管理适应证获得批准，这是目前首个且是唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。一直以来，礼来与诺和诺德并称“GLP-1双雄”，后者拥有“减肥神药”司美格鲁肽，已在国内获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407203135777061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407203135777061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","LU1093756168.USD","NVO","LLY","BK4588","BK4007","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4585","IE00BKVL7J92.USD","LU0154236417.USD"],"gpt_icon":1},{"id":"2452405946","title":"减肥药赛道“搅局者”来了，两大巨头“硬碰硬”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452405946","media":"中国基金报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452405946?lang=zh_cn&edition=full","pubTime":"2024-07-20 00:14","pubTimestamp":1721405689,"startTime":"0","endTime":"0","summary":"中国基金报记者 冯尧国内减重赛道迎来重磅级“选手”。一直以来，礼来与诺和诺德并称“GLP-1双雄”，后者拥有“减肥神药”司美格鲁肽，已在国内获批上市。如今，随着替尔泊肽加入国内减重赛道，两大巨头将在国内“硬碰硬”。如今，随着礼来的替尔泊肽注射液在国内获批，诺和诺德和礼来两大巨头在中国百亿元级GLP-1市场的正面较量也正式展开。目前，在减重赛道上，国内企业竞争激烈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072000172295ddb277&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072000172295ddb277&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603087","LU2148510915.USD","BK0060","BK0239","BK0028","BK0183","BK0188","LU0405327494.USD","688166","LU2488822045.USD","BK0196","LU1064131003.USD","LU1328615791.USD","BK0012","600276","LU0405327148.USD","LLY","LU1064130708.USD"],"gpt_icon":0},{"id":"2452742784","title":"司美格鲁肽的竞争对手来了 礼来替尔泊肽注射液体重管理适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2452742784","media":"每日经济新闻","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452742784?lang=zh_cn&edition=full","pubTime":"2024-07-19 22:16","pubTimestamp":1721398617,"startTime":"0","endTime":"0","summary":"7月19日，礼来宣布，穆峰达（替尔泊肽注射液）长期体重管理适应症获得国家药品监督管理局（NMPA）批准。据介绍，穆峰达是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407193135753480.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407193135753480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1267930730.SGD","BK4585","LU0289739699.SGD","IE00B1BXHZ80.USD","NVO","IE00B2B36J28.USD","LU1023059063.AUD","LU0198837287.USD","LU0094547139.USD","IE0002141913.USD","LU0456855351.SGD","BK4581","IE00BJJMRZ35.SGD","LU0109391861.USD","BK4007","LU1064131342.USD","LU0320765059.SGD","LU1057294990.SGD","LU1551013425.SGD","IE00BJLML261.HKD","GB00BDT5M118.USD","LU0640476718.USD","LU0882574055.USD","LU1061106388.HKD","LU0256863902.USD","LU0708995401.HKD","LU0943347566.SGD","LU1804176565.USD","LU1035775433.USD","LU0122379950.USD","IE0004445239.USD","LU1280957306.USD","BK4533","LU0114720955.EUR","IE00BJT1NW94.SGD","IE00BK4W5L77.USD","LU0417517546.SGD","LU0058720904.USD","BK4588","IE00BK4W5M84.HKD","LU0471298777.SGD","LLY","LU0061475181.USD","LU0079474960.USD","BK4534","LU0238689110.USD","LU0672654240.SGD","LU0256863811.USD","LU0471298694.HKD","LU1551013342.USD","IE00B4R5TH58.HKD"],"gpt_icon":1},{"id":"2452547353","title":"礼来(LLY)盘前涨超2% 减重适应症获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2452547353","media":"金吾财讯","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452547353?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:39","pubTimestamp":1721392760,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来(LLY)盘前涨超2%，截至发稿，报871美元。消息面上，礼来宣布，穆峰达(替尔泊肽注射液)长期体重管理适应症获得国家药品监督管理局(NMPA)批准。据悉，穆峰达是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽(GIP)/胰高糖素样肽-1(GLP-1)受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。穆峰达可结合并激活GIP受体和GLP-1受体，通过调节食欲来减少食物摄入、降低体重和减少脂肪量。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ZjBiNzEwNDA3MTQ3NjM4OTQ3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZjBiNzEwNDA3MTQ3NjM4OTQ3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278009","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0094547139.USD","BK4585","IE00BJLML261.HKD","IE00BJJMRZ35.SGD","LU0097036916.USD","IE0002141913.USD","LU1551013342.USD","BK4534","IE00B1BXHZ80.USD","LU1551013425.SGD","BK4007","LU0096364046.USD","LU0823416689.USD","LU1061106388.HKD","LLY","LU0882574055.USD","LU0256863811.USD","LU0122379950.USD","LU1623119135.USD","BK4516","BK4533","LU0289739699.SGD","IE0004445239.USD","LU1712237335.SGD","LU0061475181.USD","LU1280957306.USD","IE00BFTCPJ56.SGD","LU0466842654.USD","IE0009355771.USD","LU0385154629.USD","LU0471298694.HKD","LU0109391861.USD","LU0708995401.HKD","IE00BJT1NW94.SGD","LU1064131342.USD","LU0943347566.SGD","LU0079474960.USD","LU1035775433.USD","LU0114720955.EUR","LU0882574139.USD","LU0820561818.USD","LU1804176565.USD","LU0058720904.USD","LU0198837287.USD","GB00BDT5M118.USD","LU1023059063.AUD","LU1057294990.SGD","LU0689472784.USD","LU0820561909.HKD","LU1069344957.HKD"],"gpt_icon":1},{"id":"2452358420","title":"礼来减肥药在中国获批，将和诺和诺德直接竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2452358420","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452358420?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:30","pubTimestamp":1721392200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月19日，礼来穆峰达长期体重管理适应症获得中国国家药品监督管理局批准。穆峰达是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽/胰高糖素样肽-1受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。穆峰达可结合并激活GIP受体和GLP-1受体，通过调节食欲来减少食物摄入、降低体重和减少脂肪量。大量重磅减肥药获批，为目前主要使用诺和诺德的Ozempic的中国患者提供了更多选择。Ozempic仅被批准用于糖尿病治疗。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153452.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"礼来减肥药在中国获批，将和诺和诺德直接竞争","news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU1280957306.USD","BK4532","GB00BDT5M118.USD","IE00BZ1G4Q59.USD","LU0122379950.USD","LU0109391861.USD","LU0943347566.SGD","LU1061106388.HKD","LU0058720904.USD","LU1023059063.AUD","BK4533","LU1093756168.USD","BK4534","IE0004445239.USD","IE00B1BXHZ80.USD","LU0256863811.USD","LU0672654240.SGD","LU1551013425.SGD","BK4585","LU0097036916.USD","LU0882574055.USD","IE00BK4W5M84.HKD","BK4516","LU1057294990.SGD","LU1804176565.USD","LU0079474960.USD","LU0385154629.USD","IE00BK4W5L77.USD","LU1551013342.USD","IE00BJLML261.HKD","LLY","LU0289739699.SGD","LU0096364046.USD","LU1093756325.SGD","NVO","LU1035775433.USD","LU0094547139.USD","LU0061475181.USD","LU0417517546.SGD","LU0820561909.HKD","LU0238689110.USD","IE0002141913.USD","LU1623119135.USD","LU0708995401.HKD","LU0154236417.USD","IE00BJJMRZ35.SGD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU0471298694.HKD"],"gpt_icon":0},{"id":"2452420474","title":"BUZZ-减肥药在中国获批，礼来公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2452420474","media":"Reuters","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452420474?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:29","pubTimestamp":1721392190,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) 7月19日 - ** 礼来 股价盘前上涨2.4%至866.75美元 ** 公司称 (link) 其减肥药替西帕肽已获得中国监管机构的批准 ** 蒂塞帕肽是这家美国制药商的糖尿病药物Mounjaro（也在中国获批）和减肥药物Zepbound的活性成分** 礼来公司和丹麦制药商诺和诺德 在增加减肥药产量的竞争中遥遥领先，预计到2030年代初，减肥药市场将达到约1500亿美元的规模 (link)。** 截至上次收盘，该股今年累计上涨45.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0061475181.USD","LU0882574055.USD","LU0820561818.USD","BK4585","LU0256863811.USD","IE00BJLML261.HKD","IE00B2B36J28.USD","LU0094547139.USD","LU0097036916.USD","IE0004445239.USD","LU0640476718.USD","IE00B4R5TH58.HKD","LU1035775433.USD","LU0820561909.HKD","LU0471298694.HKD","BK4516","GB00BDT5M118.USD","LU1061106388.HKD","LU1069344957.HKD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0122379950.USD","LU0882574139.USD","IE0009355771.USD","LU0198837287.USD","LU0079474960.USD","LLY","BK4534","NVO","LU1623119135.USD","LU0708995401.HKD","LU1551013425.SGD","IE00BJT1NW94.SGD","LU1551013342.USD","BK4533","LU0466842654.USD","LU1712237335.SGD","IE00B1BXHZ80.USD","LU0823416689.USD","LU0058720904.USD","LU1280957306.USD","LU0096364046.USD","LU1064131342.USD","LU0109391861.USD","LU1804176565.USD","LU0385154629.USD","LU0689472784.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","LU0114720955.EUR"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.lilly.com","stockEarnings":[{"period":"1week","weight":-0.0326},{"period":"1month","weight":-0.0922},{"period":"3month","weight":0.1195},{"period":"6month","weight":0.2846},{"period":"1year","weight":0.8104},{"period":"ytd","weight":0.4088}],"compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0118},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.1046},{"period":"1year","weight":0.182},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.011498},{"month":2,"riseRate":0.5,"avgChangeRate":-0.002909},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015389},{"month":4,"riseRate":0.555556,"avgChangeRate":0.018718},{"month":5,"riseRate":0.422222,"avgChangeRate":0.014916},{"month":6,"riseRate":0.6,"avgChangeRate":0.02296},{"month":7,"riseRate":0.555556,"avgChangeRate":0.000069},{"month":8,"riseRate":0.409091,"avgChangeRate":0.00001},{"month":9,"riseRate":0.454545,"avgChangeRate":0.003204},{"month":10,"riseRate":0.590909,"avgChangeRate":0.014439},{"month":11,"riseRate":0.75,"avgChangeRate":0.027866},{"month":12,"riseRate":0.590909,"avgChangeRate":0.031834}],"exchange":"NYSE","name":"礼来","nameEN":"Eli Lilly"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼来,LLY,礼来股票,礼来股票老虎,礼来股票老虎国际,礼来行情,礼来股票行情,礼来股价,礼来股市,礼来股票价格,礼来股票交易,礼来股票购买,礼来股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}